Plasmid News and Research

RSS

Study shows how the plague bacteria Yersinia pestis causes disease

The bacteria responsible for the plague and some forms of food poisoning "paralyze" the immune system of their hosts in an unexpected way, according to a new study in the September 8, 2006 issue of the journal Cell.

7 Sep 2006

Swedish HIV vaccine study shows prmoise

A Swedish HIV vaccine study conducted by researchers at Karolinska Institutet (KI), Karolinska University Hospital and the Swedish Institute for Infectious Disease Control (SMI) has produced surprisingly good results.

30 Aug 2006

West Nile virus DNA vaccine shows promise in phase 1 trial

Vical Incorporated has announced that in a Phase 1 clinical trial, a West Nile virus (WNV) vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated

5 Jun 2006

A putative RNA-interference-based immune system in prokaryotes

Researchers have used computational methods to predict what could be a prokaryotic RNA-silencing mechanism similar to the eukaryotic RNA- interference system.

20 Mar 2006

Innovative treatment for critical limb ischemia

A new randomized study presented at the American College of Cardiology's 55th Annual Scientific Session investigates an innovative treatment for critical limb ischemia, or lack of arterial blood supply and oxygen to the legs, using a therapeutic approach to generate new blood vessels.

14 Mar 2006

Wobble pairs make RNA more reactive

The wealth of information contained in a strand of genetic material boils down to sequences of matched pairs of nucleotides that cellular machinery decodes to construct proteins.

13 Mar 2006

World's deadliest malaria parasite cloaking gene revealed

The world's deadliest malaria parasite, Plasmodium falciparum, sneaks past the human immune system with the help of a wardrobe of invisibility cloaks. If a person's immune cells learn to recognize one of the parasite's many camouflage proteins, the surviving invaders can swap disguises and slip away again to cause more damage. Malaria kills an estimated 2.7 million people annually worldwide, 75 percent of them children in Africa.

29 Dec 2005

Artificial mammalian origin of replication

A collaboration of researchers from Harvard Medical School and the University of Virginia, led by Dr. Anindya Dutta, has created an artificial mammalian origin of replication that will facilitate the future study of mammalian DNA replication.

2 Dec 2005

New way to generate genetically altered influenza virus

In the event of an influenza pandemic, the world's vaccine manufacturers will be in a race against time to forestall calamity.

1 Nov 2005

Gene therapy may prevent the damaging effects of radiation

Gene therapy could be used as an agent to protect normal tissues, including the esophagus and lung, from damage during a second administration of radiation therapy for non-small cell lung cancer, according to an animal study presented by University of Pittsburgh researchers at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.

16 Oct 2005

Deadly 1918 Spanish flue virus has been reconstructed and characterized

This research, reported in this week's issue of Science, is part of a larger research initiative being led by Adolfo Garcia-Sastre, PhD, Professor of Microbiology and Peter Palese, PhD, Professor and Chairman of Microbiology at Mount Sinai School of Medicine.

5 Oct 2005

Vical receives $12 Million HIV vaccine order

Vical Incorporated announced today the receipt of approximately $12.1 million in production orders for multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, under a subcontract managed by SAIC-Frederick, Inc.

16 Jun 2005

FDA grants Vical orphan-drug designation

Vical Incorporated today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has designated the company's bivalent (two-plasmid) formulation of the company's vaccine against cytomegalovirus (CMV) as an orphan drug for the prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant (HCT) and solid organ transplant (SOT) populations.

14 Jun 2005

New approach to inhibiting blood vessel growth or angiogenesis

A manmade protein with a tail of amino acids delivered to target cells can dramatically reduce blood vessel growth that obstructs vision or feeds a tumor, researchers have found.

31 May 2005

Artificial cobweb proteins for medicine

A unique material based on cobweb proteins is being created by Russian researchers of the State Research Center of Russian Federation GosNIIgentics, Scientific Research Center “Coal-Chemical Fiber”, State Research Center of Applied Microbiology in cooperation with their colleagues from Michigan University with support form the International Science and Technology Center (ISTC) (project 1033.2).

30 May 2005

Nephrogenic Syndrome of Inappropriate Antidiuresis - a new genetic disease

Two infant boys whose bodies were overloaded with excess fluid have led UCSF pediatricians to the discovery of a new genetic disease. In the process, they have discovered a rare type of mutation where different substitutions in a single amino acid cause two different, opposite genetic disorders.

4 May 2005

Experimental vaccine targeting West Nile virus

A small trial testing the safety of an experimental vaccine targeting West Nile virus (WNV) opened today at the National Institutes of Health's (NIH) Clinical Center in Bethesda, MD.

19 Apr 2005

Gene therapy shows effect in heart patients

The first double-blind, placebo-controlled randomized trial of VEGF gene injections into the heart muscle of patients with coronary artery disease with the intention of spurring growth of new blood vessels showed significant effects on heart wall motion, although blood flow was not significantly better in treated patients, according to a new study in the April 5, 2005, issue of the Journal of the American College of Cardiology.

5 Apr 2005

Promising new therapy that prompts the immune system to aid in the fight against melanoma tumors

Melanoma is a particularly deadly form of skin cancer very resistant to treatment. Researchers at H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida are testing a promising new therapy that prompts the immune system to aid in the fight against melanoma tumors.

5 Apr 2005

Vical Incorporated issued two Canadian patents

Vical Incorporated announced today the issuance of two Canadian patents on the company's core technology, which involves direct administration of polynucleotide genetic material such as DNA or RNA.

29 Mar 2005